Syndromic panel-based testing in clinical microbiology

Poornima Ramanan, Alexandra L. Bryson, Matthew J. Binnicker, Bobbi S. Pritt, Robin Patel

Research output: Contribution to journalReview articlepeer-review

91 Scopus citations


The recent development of commercial panel-based molecular diagnostics for the rapid detection of pathogens in positive blood culture bottles, respiratory specimens, stool, and cerebrospinal fluid has resulted in a paradigm shift in clinical microbiology and clinical practice. This review focuses on U.S. Food and Drug Administration (FDA)-approved/cleared multiplex molecular panels with more than five targets designed to assist in the diagnosis of bloodstream, respiratory tract, gastrointestinal, or central nervous system infections. While these panel-based assays have the clear advantages of a rapid turnaround time and the detection of a large number of microorganisms and promise to improve health care, they present certain challenges, including cost and the definition of ideal test utilization strategies (i.e., optimal ordering) and test interpretation.

Original languageEnglish (US)
Article numbere00024-17
JournalClinical Microbiology Reviews
Issue number1
StatePublished - Jan 2018


  • Molecular methods
  • Multiplex PCR
  • Syndromic testing

ASJC Scopus subject areas

  • Epidemiology
  • Immunology and Microbiology(all)
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Syndromic panel-based testing in clinical microbiology'. Together they form a unique fingerprint.

Cite this